Cargando…
Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
SIMPLE SUMMARY: Anti-PD-1 immunotherapies are approved for head and neck squamous cell carcinoma in the recurrent/metastatic setting, and utilization of these high-cost biologics is expected to increase as other indications are approved. Due to the high cost and selective response rate of these immu...
Autores principales: | Clancy, Kate, Hamill, Chelsea S., O’Neill, W. Quinn, Vu, Brandon, Thuener, Jason, Gui, Shanying, Li, Shawn, Fowler, Nicole, Rezaee, Rod, Lavertu, Pierre, Wasman, Jay, Patel, Monaliben, Shaikh, Hira, Vick, Eric, Madabhushi, Anant, Wise-Draper, Trisha M., Burkitt, Kyunghee, Teknos, Theodoros N., Pan, Quintin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508514/ https://www.ncbi.nlm.nih.gov/pubmed/34638345 http://dx.doi.org/10.3390/cancers13194861 |
Ejemplares similares
-
Treatment failure patterns are similar between p16− and p16+ oropharyngeal squamous cell carcinomas
por: Hamill, Chelsea S., et al.
Publicado: (2022) -
Incidence and medical complications of COVID-19 in the total laryngectomy population: A population-based study
por: Patel, Nilam D., et al.
Publicado: (2023) -
Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC
por: Gui, Shanying, et al.
Publicado: (2021) -
Permanent Interstitial Cesium-131 Brachytherapy in Treating High-Risk Recurrent Head and Neck Cancer: A Prospective Pilot Study
por: Kharouta, Michael, et al.
Publicado: (2021) -
p53 functional states are associated with distinct aldehyde dehydrogenase transcriptomic signatures
por: Gui, Shanying, et al.
Publicado: (2020)